Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

Shares Up 42% Following Unexplained Outbreaks

Executive Summary

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

You may also be interested in...



Bavarian Nordic Deal Opens Up Potential China Market For RSV Vaccine

As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.

4D Pharma Is Latest Biotech Casualty After Creditor Calls Time

The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.

Novartis To Cut 8,000 Jobs In Global Restructure

CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel